Multiplexed Proteomics That Scales with Your Program
BioAgilytix, an Olink certified service provider, combines years of expertise in assay design and development with high-throughput platforms to deliver quality data that supports confident clinical decisions.
Olink Target and Flex panels enable simultaneous quantitative measurement of up to 92 proteins from minimal sample volumes, delivering the multiplexing power needed for complex biomarker strategies without the sample burden of traditional platforms.
Why BioAgilytix?
- Olink Certified Service Provider
- Expert guidance in Olink panel selection to optimize biomarker strategies for your drug development program
- Flexible delivery timelines, tailored to your projects’ needs
- High reproducibility across operators*
*compared to Olink internal testing
Olink® for Biomarker Programs That Demand Precision
Biomarker strategies evolve as drug development programs progress from exploratory hypothesis testing to more focused clinical biomarker assessment. In early clinical development, multiplexed biomarker panels can help characterize biological responses, evaluate pharmacodynamic effects, and test mechanistic hypotheses.
Platform selection matters. Olink combines quantitative protein measurement with multiplexing and low sample-volume requirements, making it well suited to programs requiring:
Targeted multiplexing
Simultaneous quantitative measurement of multiple proteins using PEA technology, minimizing the cross-reactivity challenges associated with conventional multiplex immunoassays.
Flexible panel design
Choose from established Olink Target panels or build a customized Olink Flex panel from compatible assays to align testing with your specific biomarker strategy.
Sample efficiency
Low sample volume requirements for programs with limited sample availability or high-throughput needs.
Olink Target and Flex bridge the gap between traditional low-plex immunoassays and broader discovery approaches, providing quantitative, multiplexed protein measurement with the flexibility to match the panel to your biomarker strategy.
Choosing the right Olink strategy
BioAgilytix helps navigate this decision, factoring in your therapeutic area, regulatory pathway, and program timeline. Speak with a scientist early to align Olink strategy with your development plan.
| PROGRAM STAGE | SAMPLE AVAILABILITY | BIOMARKER CERTAINTY | RECOMMENDED STRATEGY |
| Exploratory/POC | Adequate | Hypothesis-driven | Target (predefined panel) |
| Phase 1–2 Validation | Limited | Refined but customizable | Flex (custom 5-30 proteins) |
| Phase 2–3 Registration | Very limited | Defined biomarker set | Flex (optimized panel) |
How Olink Compares: Multiplexing Strategies
The right platform depends on your biomarker question, regulatory context, and resources. BioAgilytix helps navigate this decision and often deploys multiple platforms within a single program, leveraging Olink for broad biomarker profiling to inform hypothesis generation, complemented by validated analytical platforms for primary endpoint assessment.
| CAPABILITY | OLINK TARGET/FLEX | ELISA/MSD/SINGLEPLEX | LUMINEX MULTIPLEX | MASS SPEC (LC/MS) |
| Targets per assay | 5–92 | 1 | 50+ | 50+ |
Sample volume | 1–4 µL | 50–100 µL | 25–50 µL | 10–100 mL |
| Throughput | High (96-well format, rapid turnaround) | Moderate–Low (sequential) | High | High |
| Absolute quantification | Target 96: relative Target 48/Flex: absolute | Yes (with standards) | Yes (with standards) | Yes (with standards) |
| Ideal program phases | Discovery → Phase 3 | Exploratory or highly validated single targets | Phase 1–2 validation | Discovery or specialized applications |
POSTER
Qualification of a 48-Plex Cytokine Olink® Panel to Support Rare Disease and Pediatric Clinical Studies
Measuring pathway-specific, physiologically relevant biomarkers is critical
for successful development, testing, and approval of therapeutics.
However, selection of appropriate biomarkers for novel modalities and/or
rare disease indications can be challenging. Biomarker analysis for rare
diseases and pediatric clinical studies can benefit from multiplexed
platforms that can look at numerous analytes with minimal sample volume.
